

FLORIDA HOUSE OF REPRESENTATIVES BILL ANALYSIS

This bill analysis was prepared by nonpartisan committee staff and does not constitute an official statement of legislative intent.

BILL #: [CS/HB 353](#)

TITLE: Sickle Cell Care Management and Treatment
Continuing Education

SPONSOR(S): Robinson, F.

COMPANION BILL: [CS/SB 844](#) (Jones)

LINKED BILLS: None

RELATED BILLS: None

Committee References

[Health Professions & Programs](#)

15 Y, 0 N, As CS



[Health & Human Services](#)

23 Y, 0 N

SUMMARY

Effect of the Bill:

CS/HB 353 requires information related to the treatment of pain for patients with sickle cell disease to be included in the continuing education course on controlled substance prescribing required for licensure renewal of certain health care practitioners registered to prescribe controlled substances.

Fiscal or Economic Impact:

The bill has no fiscal impact on state or local government and a nominal fiscal impact on the private sector.

[JUMP TO](#)

[SUMMARY](#)

[ANALYSIS](#)

[RELEVANT INFORMATION](#)

[BILL HISTORY](#)

ANALYSIS

EFFECT OF THE BILL:

CS/HB 353 requires information related to treatment of pain for patients with [sickle cell disease](#) (SCD) to be added to the [continuing education](#) (CE) course on controlled substance prescribing that is required for the biennial licensure renewal of allopathic physicians¹ and osteopathic physicians² [registered with the United States Drug Enforcement Agency](#) (DEA) to prescribe [controlled substances](#).³ (Section [1](#)).

The addition of this material ensures that physicians authorized to prescribe controlled substances have some familiarity with the unique features of [SCD pain crises](#) and may prevent undertreatment.

The bill provides an effective date of July 1, 2026. (Section [2](#)).

FISCAL OR ECONOMIC IMPACT:

PRIVATE SECTOR:

CE providers that offer the controlled substances course required under [s. 456.44, F.S.](#), will need to update the course content to incorporate the content required by the bill, in order for the course to continue satisfying the requirement, which may generate a nominal cost.

¹ Allopathic (medical) physicians are licensed under ch. 458, F.S.

² Osteopathic physicians are licensed under ch. 459, F.S.

³ While this requirement applies to all prescribers registered with the DEA, a practitioner is exempt from the CE requirement in [s. 456.0301, F.S.](#), if they are otherwise required under the applicable practice act to complete a minimum of two hours of CE coursework on the safe and effective prescribing of controlled substances. Dentists and podiatric physicians are required in the respective practice acts to complete a minimum of two hours on the subject, while APRNs and PAs must complete a minimum of three hours pursuant to their own practice acts.

STORAGE NAME: h0353b.HHS

DATE: 2/25/2026

RELEVANT INFORMATION

SUBJECT OVERVIEW:

Health Care Professional Licensure & Regulation

The Division of Medical Quality Assurance (MQA), within the Department of Health (DOH), has general regulatory authority over health care practitioners.⁴ The MQA works in conjunction with 22 professional boards and four councils to license and regulate more than 40 health care professions.⁵ The requirements for initial licensure vary by profession. Professional boards are responsible for approving or denying applications for initial licensure, establishing continuing medical education requirements, and are involved in disciplinary hearings.⁶ After receiving initial licensure to practice a health care profession, practitioners are generally required to renew their licenses on a biennial basis.⁷

As a condition of biennial licensure renewal, health care practitioners must complete [continuing education](#) (CE) courses. The number of CE course hours that a health care practitioner must complete and the prescribed subjects vary by profession. A health care practitioner may be subject to disciplinary action for failure to comply with CE requirements.⁸

Controlled Substance Prescribing

Chapter 893, F.S., the Florida Comprehensive Drug Abuse Prevention and Control Act, classifies [controlled substances](#) into five categories, called schedules. These schedules regulate the manufacture, distribution, preparation, and dispensing of the substances listed therein. The distinguishing factors between the different drug schedules are the “potential for abuse”⁹ of the substance and whether there is a currently accepted medical use for the substance.¹⁰

Opioids are highly effective pain relievers, and as such are commonly used to treat acute and chronic severe pain. However, there are significant risks associated with opioid use, including physical dependence, addiction, and potential for overdose with repeated use.¹¹ Due to their high potential for abuse, opioids are generally categorized as schedule II-controlled substances and have an accepted, but severely restricted, medical use in the United States.¹²

Current law allows physicians,¹³ physician assistants (PAs),¹⁴ advanced practice registered nurses (APRNs),¹⁵ podiatric physicians,¹⁶ and dentists¹⁷ to be authorized to prescribe Schedule II,¹⁸ Schedule III,¹⁹ and Schedule IV²⁰

⁴ Pursuant to [s. 456.001\(4\), F.S.](#), health care practitioners are defined to include acupuncturists, physicians, physician assistants, chiropractors, podiatrists, naturopaths, dentists, dental hygienists, optometrists, nurses, nursing assistants, pharmacists, midwives, speech language pathologists, nursing home administrators, occupational therapists, respiratory therapists, dietitians, athletic trainers, orthotists, prosthetists, electrologists, massage therapists, clinical laboratory personnel, medical physicists, dispensers of optical devices or hearing aids, physical therapists, psychologists, social workers, mental health counselors, and psychotherapists, among others.

⁵ Department of Health, Division of Medical Quality Assurance Annual Report (2025). Available at <https://www.floridahealth.gov/wpcontent/uploads/2026/01/2025.10.31.FY24-25MQAAR-FINAL1-1.pdf> (last visited February 19, 2026).

⁶ [Ss. 456.013, F.S.](#), & 456.072, F.S.

⁷ See, [s. 456.004, F.S.](#)

⁸ [S. 456.072\(3\), F.S.](#)

⁹ [S. 893.02\(22\), F.S.](#), defines “potential for abuse” to mean that a substance has properties as a central nervous system stimulant or depressant or a hallucinogen that create a substantial likelihood of its being: 1) used in amounts that create a hazard to the user’s health or safety of the community; 2) diverted from legal channels and distributed through illegal channels; or 3) taken on the user’s own initiative rather than on the basis of professional medical advice.

¹⁰ See [s. 893.03, F.S.](#)

¹¹ National Institute on Drug Abuse, *How Do Opioids Affect the Brain and Body?* (2020). Available at <http://www.drugabuse.gov/publications/research-reports/prescription-drugs/opioids/how-do-opioids-affect-brain-body> (last visited February 19, 2026).

¹² [S. 893.03\(2\), F.S.](#)

¹³ Allopathic physicians licensed under ch. 458, F.S., and osteopathic physicians licensed under ch. 459, F.S.

¹⁴ See, [ss. 458.347\(4\)\(f\), F.S.](#), and [459.022\(8\)\(c\), F.S.](#)

¹⁵ See, [s. 464.012\(6\)\(a\), F.S.](#)

controlled substances to treat chronic malignant pain, pursuant to the requirements and restrictions in their respective practice acts. To be authorized, practitioners must designate themselves as controlled substance prescribing practitioners on their practitioner profiles and comply with the standards of practice as specified in [s. 456.44, F.S.](#), and in rules established by the respective professional board.²¹

Federal law requires a practitioner to [register with the United States Drug Enforcement Administration](#) (DEA) before he or she may lawfully prescribe a controlled substance.²² In order to register with the DEA, a practitioner must complete at least 8 hours of training on treatment and management of patients with opioid or other substance use disorders, safe pharmacological management of dental pain and screening, brief intervention, and referral for appropriate treatment of patients with or at risk of developing opioid or other substance use disorders.²³

Controlled Substance Continuing Education

Current law requires all health care practitioners who are registered with the DEA to prescribe controlled substances to complete a board-approved 2-hour CE course on prescribing controlled substances as a condition of licensure renewal.²⁴ The course must address:²⁵

- The current standards for prescribing controlled substances, particularly opiates;
- Alternatives to controlled substances;
- Nonpharmacological therapies;
- Emergency opioid antagonists; and
- The risks of opioid addiction following all stages of treatment in the management of acute pain.

Current law does not require this CE course to include information related to treatment of pain associated with sickle cell disease.

The controlled substances course must be offered by a statewide professional association of physicians in this state that is accredited to provide educational activities designated for the American Medical Association Physician's Recognition Award Category 1 Credit or the American Osteopathic Category 1-A continuing medical education credit.²⁶ The Florida Medical Association and the Florida Osteopathic Medical Association are the only entities that meet these criteria.

A practitioner is exempt from this specific CE requirement if otherwise required under the applicable practice act to complete a minimum of two hours of CE coursework on "safe and effective" prescribing of controlled substances.²⁷ Dentists²⁸ and podiatric physicians²⁹ are required by their practice acts to complete a minimum of

¹⁶ See, [s. 461.003\(5\), F.S.](#)

¹⁷ See, [s. 466.02751, F.S.](#)

¹⁸ Schedule II substances have a high potential for abuse and have a currently accepted but severely restricted medical use in the United States, including substances such as amphetamine, codeine, fentanyl, methamphetamine, morphine, raw opium, and oxycodone. See, [s. 893.03\(2\), F.S.](#)

¹⁹ Schedule III substances have a potential for abuse less than the substances contained in Schedules I and II and have a currently accepted medical use in the United States, including substances such as anabolic steroids and ketamine. See, [s. 893.03\(3\), F.S.](#)

²⁰ Schedule IV substances have a low potential for abuse relative to substances in Schedule III and have a currently accepted medical use in the United States, including substances such as benzodiazepines and barbiturates. See, [s. 893.03\(4\), F.S.](#)

²¹ [S. 456.44\(2\), F.S.](#), Rule 64B18-23.002(2)(g), F.A.C.

²² 21 U.S.C. § 802(10); 21 U.S.C. § 822(a)(2); 21 C.F.R. § 1301.11(a).

²³ 21 U.S.C. § 823(m)(1).

²⁴ [S. 456.0301\(1\), F.S.](#)

²⁵ *Id.*

²⁶ *Id.*

²⁷ [S. 456.0301\(1\)\(a\), F.S.](#)

²⁸ See, [s. 466.0135, F.S.](#)

²⁹ See, [s. 461.007\(3\), F.S.](#)

two hours on the subject, while APRNs³⁰ and PAs³¹ must complete a minimum of three hours pursuant to their own practice acts. As such, the required course content as specified by [s. 456.0301, F.S.](#), only expressly applies to allopathic and osteopathic physicians registered with the DEA.

Sickle Cell Disease

[Sickle cell disease](#) (SCD) is an inherited blood disorder affecting approximately 100,000 people in the United States.³² SCD is both a rare disease, as it affects fewer than 200,000 people nationally,³³ as well as the most common inherited blood disorder in the United States.³⁴ More than 90 percent of people affected by SCD in the United States are of Black or African American heritage.³⁵ SCD is a lifelong condition that is present and detectable at birth; children born in the United States are screened for SCD at birth in every state.³⁶ Florida began screening newborns for SCD in 1988.³⁷

There are many forms of SCD of varying levels of severity, all of which are inherited and affect the body's red blood cells. Sickle cell anemia (SCA) is the most common and severe form of the disease; in SCA, abnormal hemoglobin causes red blood cells to become rigid and buckle into the iconic sickle shape. The deformed red blood cells damage blood vessels and over time contribute to a cascade of negative health effects beginning in infancy, such as intense vasocclusive pain episodes, strokes, organ failure, and recurrent infections.³⁸

The severity of complications from SCD generally worsen as people age, but treatment and prevention strategies can mitigate complications and lengthen the lives of people with SCD.³⁹ SCD was historically perceived as a childhood disease due to high rates of childhood mortality, however, more than 90 percent of those living with the disease today are expected to survive into adulthood.⁴⁰ Roughly 60 percent of individuals with SCD in the US today are adults, but the life expectancy of individuals with SCD remains approximately 22 years shorter than the general population.⁴¹

Management of Sickle Cell Disease

SCD management primarily focuses on treating and preventing complications caused by the disease such as infection, stroke, vision loss, severe anemia, and acute pain episodes. The most well-researched treatments for SCD relate to mitigating the risk of infection and stroke in children. While there have been developments in recent years, there remains a lack of research-driven data specific to adult populations with SCD and a knowledge gap among providers regarding the best practice in managing and treating complications of SCD.⁴²

³⁰ See, [s. 464.013\(3\)\(b\), F.S.](#)

³¹ See, [ss. 458.347\(4\)\(e\), F.S.](#), and [459.022\(4\)\(e\), F.S.](#)

³² Centers for Disease Control and Prevention, *Data & Statistics on Sickle Cell Disease*. Available at https://www.cdc.gov/sickle-cell/data/?CDC_AAref_Val=https://www.cdc.gov/ncbddd/sicklecell/data.html (last visited February 5, 2026).

³³ National Organization for Rare Disorders, *NORD Rare Disease Database*. Available at <https://rarediseases.org/rare-diseases/> (last visited February 5, 2026).

³⁴ American Society of Hematology, *Sickle Cell Disease*. Available at <https://www.hematology.org/education/patients/anemia/sickle-cell-disease> (last visited February 5, 2026).

³⁵ *Supra*, note 32.

³⁶ National Organization for Rare Disorders, *Sickle Cell Disease* (2024). Available at <https://rarediseases.org/rare-diseases/sickle-cell-disease/> (last visited February 5, 2026).

³⁷ See, Rule 64C-7.002, F.A.C.

³⁸ *Supra*, note 36.

³⁹ *Supra*, note 32.

⁴⁰ DiMartino, L. D., Baumann, A. A., Hsu, L. L., Kanter, J., Gordeuk, V. R., Glassberg, J., Treadwell, M. J., Melvin, C. L., Telfair, J., Klesges, L. M., King, A., Wun, T., Shah, N., Gibson, R. W., Hankins, J. S., & Sickle Cell Disease Implementation Consortium (2018). *The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease*. American journal of hematology, 93(12), E391–E395. <https://doi.org/10.1002/ajh.25282>.

⁴¹ Lubeck D, Agodoa I, Bhakta N, et al. (2019) *Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease*. JAMA Netw Open. 2019;2(11):e1915374. doi:10.1001/jamanetworkopen.2019.15374. Available at <https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2755485> (last visited February 8, 2026).

⁴² Adams-Graves, P. & Bronte-James, L. *Recent Treatment Guidelines for Managing Adult Patients with Sickle Cell Disease: Challenges in Access to Care, Social Issues, and Adherence*. (2016). Expert Review of Hematology, 9:6, 511-614.

The nature of SCD inherently leads to a greater use of health care services compared to the general population, but gaps in access to appropriate care are common and lead to unmitigated health crises and a greater consumption of costly emergency medical services.⁴³ Health care practitioners who have not specialized in the treatment of SCD express discomfort in prescribing essential treatments for SCD,⁴⁴ and a lack of knowledge regarding recent treatment developments.⁴⁵

Access to adequate care is especially challenging for young adults transitioning from pediatric to adult care settings.⁴⁶ While SCD has historically been associated with childhood mortality, more than 90 percent of those living with the disease are expected to survive into adulthood today.⁴⁷ The system of care for SCD has developed with a focus on pediatric patients; as a result, patients with SCD are more likely to receive well-managed preventative care as children through specialized pediatric programs. Patients aging out of pediatric care and transitioning into adult care are less likely to have access to consistent and appropriate SCD care, which leads to higher rates of emergency department reliance than other age groups.⁴⁸

Use of Opioids in Treating SCD Pain Crises

Vaso-occlusive crises (VOCs) are acute episodes of severe pain and the most common reason for emergency department and hospital admissions for individuals with SCD.⁴⁹ The pain caused by VOCs is severe and requires immediate medical treatment. SCD patients with three or more admissions to the hospital for sickle cell pain are at an increased risk of death.⁵⁰ Immediate treatment with opioids is consistent with the standard of care for patients with SCD who present at the emergency department experiencing severe pain.⁵¹

According to both the American Society of Hematology SCD Guidelines⁵² and the American College of Emergency Physicians (ACEP), the severity of sickle cell pain necessitates pain medication be administered within 60 minutes of arrival at the emergency department, regardless of space constraints. ACEP further recommends not to wait for

<http://dx.doi.org/10.1080/17474086.2016.1180242> See also, Smeltzer, M.P., Howell, K.E., Treadwell, M. (2021). *Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA*. BMJ Open 2021. DOI: 10.1136/bmjopen-2021-050880

⁴³ DiMartino, L. D., Baumann, A. A., Hsu, L. L., Kanter, J., Gordeuk, V. R., Glassberg, J., Treadwell, M. J., Melvin, C. L., Telfair, J., Klesges, L. M., King, A., Wun, T., Shah, N., Gibson, R. W., Hankins, J. S., & Sickle Cell Disease Implementation Consortium (2018). *The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease*. American journal of hematology, 93(12), E391–E395. <https://doi.org/10.1002/ajh.25282>. See also, Brousseau, D.C., Owens, P.L., Mosso, A.L., Panepinto, J.A., Steiner, C.A. (2010). *Acute Care Utilization and Rehospitalizations for Sickle Cell Disease*. JAMA. 2010;303(13):1288–1294. doi:10.1001/jama.2010.378

⁴⁴ Lanzkron S, Haywood C Jr, Hassell KL, Rand C. *Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the sickle cell disease adult provider network*. (2008) Journal of the National Medical Association. 100(8): 968-973. [https://doi.org/10.1016/S0027-9684\(15\)31419-X](https://doi.org/10.1016/S0027-9684(15)31419-X)

⁴⁵ Robinson, K., Esagro, R., Cooper, S., LoPresti, M., & Carson, B. *Identifying and Addressing Knowledge and Confidence Gaps Regarding the Management of Patients with Sickle Cell Disease Via Engaging Continuing Medical Education*. (2023). *Blood* 142 (Supplement 1): 7228. doi: <https://doi.org/10.1182/blood-2023-177576>

⁴⁶ Hemker, B., Brousseau, D., Yan, K., Hoffmann, R., & Panepinto. *When Children with Sickle Cell Disease Become Adults: Lack of Outpatient Care Leads to Increased Use of the Emergency Department* (2011). *American Journal of Hematology*. 86:10, 863-865. <https://doi.org/10.1002/ajh.22106>

⁴⁷ *Id.*

⁴⁸ Blinder, M. A., Duh, M. S., Sasane, M., Trahey, A., Paley, C., & Vekeman, F., *Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease*. (2015). *The Journal of emergency medicine*, 49(4), 513–522.e1. <https://doi.org/10.1016/j.jemermed.2014.12.080>

⁴⁹ Ballas, S., *Opioids and Sickle Cell Disease: From Opium to the Opioid Epidemic* (2021). *Journal of Clinical Medicine*. Cardeza Foundation for Hematologic Research. Paper 67. Available at https://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1065&context=cardeza_foundation (last visited February 19, 2026).

⁵⁰ American College of Emergency Physicians, *Sickle Cell: Guidance on evaluation and management of patients with Sickle Cell Disease in the ED* (2023). Available at <https://pocctools.acep.org/POCCTool/SickleCell/df0c5789-695b-4ceb-8fde-9f3db269a26d> (last visited February 8, 2026).

⁵¹ *Id.* See also, Brandow, A.M., et al., *American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain*. (2020). *Blood Adv* 2020; 4 (12): 2656–2701. doi: <https://doi.org/10.1182/bloodadvances.2020001851>

⁵² American Society of Hematology, *ASH Clinical Practice Guidelines: ASH SCD Guidelines: Management of Acute and Chronic Pain* (2020). Available at <https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/scd-guidelines-management-of-acute-and-chronic-pain> (last visited February 7, 2026).

lab results before initiating pain medications, as there are no lab values that can confirm or rule-out a sickle cell pain crisis.⁵³ While non-opioid and non-pharmacologic interventions may serve as an adjunct for treating pain in SCD patients, there are caveats to their use. For example, non-opioid pain analgesics, such as nonsteroidal anti-inflammatory drugs (NSAIDs), are often contraindicated for patients with SCD due to their vasoconstrictive effects and other systemic side effects that may not be immediately obvious.⁵⁴

In spite of the clinical evidence supporting the treatment of SCD-related pain with opioids, especially in emergency care settings, patients with SCD who present to emergency care settings are often perceived as drug seekers or abusers and have their pain severity doubted and undertreated.⁵⁵ Educational gaps and biases among providers, staff, and patients create barriers to communication and trust, and erode the provider–patient relationship, which can result in inadequate or inappropriate treatment of patients.⁵⁶

RECENT LEGISLATION:

YEAR	BILL #/SUBJECT	HOUSE/SENATE SPONSOR(S)	OTHER INFORMATION
2025	HB 333 - Sickle Cell Care Management and Treatment Education	Robinson, F./ Rouson	Died in the Health Care Professions & Programs Subcommittee
2024	CS/HB 349 - Sickle Cell Care Management and Treatment Education	Robinson, F./ Rouson	Died in the Health & Human Services Committee

BILL HISTORY

COMMITTEE REFERENCE	ACTION	DATE	STAFF DIRECTOR/ POLICY CHIEF	ANALYSIS PREPARED BY
Health Professions & Programs Subcommittee	15 Y, 0 N, As CS	2/11/2026	McElroy	Osborne
THE CHANGES ADOPTED BY THE COMMITTEE:	Removed a new continuing education requirement for physicians and nurses related to sickle cell disease.			
Health & Human Services Committee	23 Y, 0 N	2/24/2026	Calamas	Osborne

THIS BILL ANALYSIS HAS BEEN UPDATED TO INCORPORATE ALL OF THE CHANGES DESCRIBED ABOVE.

⁵³ American College of Emergency Physicians, Sickle Cell: Guidance on evaluation and management of patients with Sickle Cell Disease in the ED (2023). Available at <https://pocools.acep.org/POCTool/SickleCell/df0c5789-695b-4ceb-8fde-9f3db269a26d> (last visited February 8, 2026).

⁵⁴ *Supra*, notes 49 & 50.

⁵⁵ DiMartino, L. D., Baumann, A. A., Hsu, L. L., Kanter, J., Gordeuk, V. R., Glassberg, J., Treadwell, M. J., Melvin, C. L., Telfair, J., Klesges, L. M., King, A., Wun, T., Shah, N., Gibson, R. W., Hankins, J. S., & Sickle Cell Disease Implementation Consortium (2018). *The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease*. American journal of hematology, 93(12), E391–E395. <https://doi.org/10.1002/ajh.25282>

⁵⁶ Glassberg, G., *Improving Emergency Department-Based Care of Sickle Cell Pain* (2017). Hematology. American Society of Hematology. Education Program, 2017(1), 412–417. <https://doi.org/10.1182/asheducation-2017.1.412>